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Summary
Background In a retrospective analysis of a prospec-
tive single center registry we compared the use of bi-
valirudin, unfractionated heparin (UFH) monother-
apy, UFH + abciximab in 1240 consecutive patients
with acute coronary syndrome (ACS) undergoing stent
implantation.
Results Bivalirudin was associated with tendentially
reduced in-hospital minor or major bleeding rates
compared to UFH monotherapy (5.9% vs. 9.4% ad-
justed odds ratio (OR) 0.82, 95% confidence interval
CI 0.45–1.51, p = 0.53) and compared to the pooled
UFH group (5.9% vs. 11.9%, adjusted OR 0.62, 95% CI
0.36–1.08, p = 0.09) but with significantly lower bleed-
ing hazards compared to UFH + abciximab (5.9% vs.
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16%, adjusted OR 0.41, 95% CI 0.22–0.78, p < 0.01).
After 3 years of follow-up, adjusted cardiovascular
mortality rates were similar between all groups, par-
ticularly between bivalirudin vs. UFH monotherapy
(hazard ratio HR 1.12, 95% CI 0.58–2.16, p = 0.73) and
vs. UFH + abciximab (HR 0.91, 95% CI 0.40–2.10, p =
0.83). Acute or subacute stent thrombosis occurred at
a rate of 0.8% with no significant differences between
the groups.
Conclusions This retrospective analysis in a real world
situation of medium to high-risk ACS patients under-
going invasive revascularization confirmed the results
of most large-scale randomized trials by demonstrat-
ing reduced bleeding rates in favor of bivalirudin vs.
UFH +GPI but with no significant differences between
treatment strategies for long-term all-cause and car-
diovascular mortality.
Keywords Bivalirudin · Acute coronary syndrome ·
Percutaneous coronary intervention · Anticoagula-
tion · Heparin
Introduction
Invasive revascularization with stent implantation
is the standard of care for the majority of patients
presenting with acute coronary syndrome (ACS) and
improves clinical outcomes compared to a more con-
servative approach [1]. Recent studies have suggested
that novel antithrombotic and antiplatelet strategies,
namely fondaparinux [2], bivalirudin [3, 4], ticagrelor
[5] and rivaroxaban in combination with dual an-
tiplatelet therapy [6] may reduce mortality in ACS
patients. In recent large-scale prospective random-
ized trials, the favorable pharmacological action of
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bivalirudin translated into lower 30-day major bleed-
ing rates compared to unfractionated heparin (UFH)
plus a glycoprotein IIb/IIIa inhibitor (GPI) and also
vs. UFH monotherapy but exhibited similar or even
worse rates in ischemic events depending on study
design, patient selection and concomitant therapy
[4, 7–9]. While previous guidelines have led to an
increased use of bivalirudin in the USA, bivalirudin
is infrequently used in ACS patients undergoing per-
cutaneous coronary interventions (PCI) in western
Europe (approximately 10% of patients) with the ex-
ception of some highly specialized centers. Of note,
international trials have mainly compared bivalirudin
(monotherapy) with UFH + GPI in ACS patients and
real world observations vs. UFH monotherapy are
scarce [3, 9–11]. Accordingly, we investigated the
efficacy and safety of bivalirudin compared to hep-
arin-based strategies in patients with ST-elevation or
non-ST-elevation myocardial infarction (STEMI and
NSTEMI, respectively) referred for acute angiography




In this post hoc analysis of a prospective registry, an-
tithrombotic therapy (as used per the discretion of the
interventional cardiologist), cardiovascular risk fac-
tors, comorbidities and coronary morphology were
evaluated in 1240 consecutive patients with ACS who
were referred for PCI with stent implantation between
January 2004 and June 2012. We included STEMI pa-
tients presenting with ST-segment elevation of 1 mm
or more in two or more contiguous leads, as well as
NSTEMI patients with elevated troponin I, troponin T
or creatine kinase MB levels (CK-MB) above the up-
per limit of normal and/or ST-segment depression of
≥1 mm. Patients lacking laboratory or electrocardio-
graphic evidence suggestive of high-risk ACS were ex-
cluded from this analysis as were patients referred for
rescue PCI after thrombolytic therapy, patient records
with a missing cause of death (n = 4) or patients who
were in cardiogenic shock at any time during index
hospitalization. In contrast to current practice, PCI
was performed by the femoral approach in the vast
majority of patients included into the registry (93%).
The study was performed in accordance with the Dec-
laration of Helsinki and approved by the local ethics
committee (EK 10-046-VK_NZ).
Study treatment
As the institutional standard of care, all patients re-
ceived aspirin and clopidogrel as a 600 mg loading
dose (LD) followed by 75 mg maintenance dose (MD),
prasugrel (60 mg LD followed by 10 mg MD except
in patients >75 years or <60 kg who received 5 mg
MD) or ticagrelor (180 mg LD followed by 180 mg
MD). Prasugrel was used in most STEMI patients and
in high-risk NSTEMI patients starting in 2010. All
STEMI patients were pretreated with UFH (60 IU/kg
i.v. bolus but maximum 5000 U) by emergency physi-
cians. All NSTEMI patients received anticoagulation
with enoxaparin, UFH or fondaparinux until diagnos-
tic coronary angiography. In the case of fondaparinux
being given prior to catheterization, UFH was exclu-
sively added in the catheterization laboratory as i.v.
bolus of 85 IU/kg body weight. The NSTEMI patients
who were pretreated with enoxaparin or UFH and
STEMI patients either received UFH in the catheteri-
zation laboratory or bivalirudin, which was adminis-
tered as bolus and infusion only until the end of the
intervention due to practical reasons (both STEMI and
NSTEMI: 0.75 mg/kg bolus, 1.75 mg/kg/h infusion). If
extended bed rest after PCI was indicated, enoxaparin
was administered at a thrombosis prophylactic dose
until full mobilization. Abciximab was used in the
presence of increased thrombus load in the infarct-re-
lated artery or as bail-out therapy in patients with slow
or no-reflow in the recommended dosage (bolus +in-
fusion for 12 h). Moreover, patients received optimal
secondary prevention, i. e. statin therapy with a target
low-density lipoprotein (LDL) of less than 70 mg/dl
(1.8 mmol/l) but also other guideline-recommended
treatment, such as beta blockers, angiotensin convert-
ing enzyme (ACE) inhibitors and/or angiotensin re-
ceptor blockers. All ACS patients received parenteral
anticoagulation, aspirin and an approved P2Y12 in-
hibitor, as early as possible, usually in the emergency
room of the department but in the majority before the
catheter laboratory. Decisions regarding the choice of
P2Y12 inhibitor, bail-out use of abciximab, access site,
performance of thrombus aspiration, stent type and
duration of dual antiplatelet therapy were left to the
physician’s discretion.
Study outcome
The primary efficacy endpoint was cardiovascular
mortality after 3 years of follow-up. As secondary effi-
cacy endpoints we evaluated all-cause mortality after
3 years of follow-up as well as acute and subacute
stent thrombosis. Mortality data for all patients were
obtained from Statistics Austria, an independent and
non-profit-making federal institution under public
law that supports scientific services. Cases of death
occurring in Austria are centrally recorded by Statis-
tics Austria and data are made available for authorized
institutions on request. Cause of death is reported
by means of the International Statistical Classifica-
tion of Disease and Related Health Problems (ICD-
10). A cardiovascular death was adjudicated when an
ICD-10 chapter I00-I99 diagnosis was reported as the
cause of death. Acute and subacute stent thrombosis
was evaluated and reported according to the defini-
tion proposed by the Academic Research Consortium
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[12]. The primary safety endpoint was a composite
of in-hospital minor or major bleeding events based
on the Thrombolysis in Myocardial Infarction (TIMI)
classification. As tertiary endpoint we registered
days from PCI to hospital discharge. This tertiary
endpoint was compared between patients with and
without bleeding complications and between the
different antithrombotic strategies. For the detec-
tion of in-hospital bleeding, levels of hemoglobin
and hematocrit were measured before and daily af-
ter PCI until hospital discharge. For categorization
of periprocedural bleeding events, we calculated the
difference in hemoglobin concentrations between the
most recent hemoglobin value before PCI and the
hemoglobin nadir post-PCI. In accordance with the
TIMI bleeding classification [13] the following cut-off
levels were used: minor bleeding was defined as a
drop in hemoglobin from ≥3 to <5 g/dl or a ≥10% de-
crease in hematocrit and major bleeding was defined
as a drop in hemoglobin ≥5 g/dl or a ≥15% decrease
in hematocrit.
Clinical outcome data were compared between the
pooled bivalirudin group (with or without GPI use) vs.
UFH monotherapy, vs. UFH + abciximab and vs. the
pooled UFH group. As the group of patients receiving
bivalirudin + abciximab represented only 1.1% of the
whole cohort (14 patients), a separate analysis for this
subgroup was not performed.
Statistical methods
Descriptive statistics were performed on baseline vari-
ables and stratified by the different treatment groups.
Discrete characteristics are expressed as frequency
counts and percentages and differences were deter-
mined by the χ2-test. Continuous characteristics are
expressed as means and standard deviations or me-
dians (where appropriate), with differences examined
with the Kruskal-Wallis test throughout all groups or
the Mann-Whitney test for the comparison of two
treatment arms. The level of significance used for all
tests was a two-sided p-value of 0.05.
Univariate analysis in the Cox proportional haz-
ards and the logistic regression model was performed
to estimate mortality and bleeding hazards between
different antithrombotic treatments. A 1:1 matched
propensity score for the abovementioned two-group
comparisons was obtained in order to account for
confounding variables. Covariates were chosen based
on significant differences between groups (Table 1)
and well-established risk factors, e.g. age, gender,
body mass index (BMI), estimated glomerular filtra-
tion rate (eGFR), baseline hemoglobin, hypertension,
hyperlipidemia, smoking, diabetes, clinical presenta-
tion (STEMI or NSTEMI), type of stent, number of
diseased vessels, previous MI, previous invasive revas-
cularization, peripheral artery disease, prior stroke or
transient ischemic attack (TIA), heart failure, history
of malignancies, atrial fibrillation, vascular access site,
year of index hospitalization, statin treatment and an-
tiplatelet substance. The corresponding propensity
scores were then included in the Cox regression (mor-
tality) and logistic regression (in-hospital bleeding)
analyses for the two-group comparisons.
Likewise, the impact of bleeding and antithrom-
botic therapy on the duration of hospitalization was
analyzed in a linear regression model. The Software
Package for Social Sciences version 22 (SPSS, Chicago,
IL) was used for all statistical calculations.
Results
Study population
Registered baseline characteristics included cardio-
vascular risk factors, comorbidities, coronary mor-
phology, medication at hospital discharge and labora-
tory findings (Table 1). From 1240 patients presenting
with ACS and undergoing PCI plus stent implanta-
tion, 632 (51.4%) patients presented with STEMI.
Of the total cohort, 273 (22%) received bivalirudin
monotherapy in the catheterization laboratory, 14
(1.1%) received bivalirudin + abciximab, 596 (48.1%)
received UFH alone and 357 (28.8%) patients received
UFH + abciximab. The NSTEMI patients more fre-
quently received bivalirudin, while STEMI patients
more frequently received UFH + abciximab (p < 0.01,
Table 1). The utilization of the different antithrom-
botic strategies over time is presented in Fig. 3. There
was a steep increase in bivalirudin use, starting from
2009 (p for trend <0.01).
Similarities as well as significant differences re-
garding baseline characteristics were detected be-
tween the study groups. While patients receiving
UFH monotherapy, as compared to the pooled bi-
valirudin group were similar with respect to age,
diabetes, hypertension, previous stroke, myocardial
infarction or PCI, heart failure, coronary morphology
and other characteristics (Table 1), these patients
had lower levels of hemoglobin at admission (median
14.1 g/dl vs. 13.8 g/dl, p < 0.01) and lower levels of
estimated glomerular filtration rate (eGFR, median
91.6 ml/min vs. 82.7 ml/min, p = 0.01). Patients
receiving UFH + abciximab were younger (median
age 63 years vs. 59 years, p < 0.01), had higher lev-
els of baseline hemoglobin (median 14.1 mg/dl vs.
14.5 mg/dl, p < 0.01) and had a higher eGFR than
patients of the pooled bivalirudin cohort (median
eGFR 91.6 ml/min vs. 96.5 ml/min, p < 0.01). Risk
factors and comorbidities, such as diabetes, hyper-
tension, prior stroke, TIA or a history for malignant
tumors were more prevalent in the pooled bivalirudin
group, as opposed to UFH + abciximab. Discharge
medications including ACE inhibitors, ARBs and beta
blockers were similar between groups, while patients
treated with UFH monotherapy received adequate
statin therapy at hospital discharge less frequently
than patients treated with bivalirudin or with UFH +
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Table 1 Baseline characteristicsof patients stratifiedbyantithrombotic treatmentgroups




UFH monotherapy n =
596




Gender Male 66.80% 64.80% 63.30% 74.20% 0.002
– Female 33.20% 35.20% 36.70% 25.80% –
Clinical presentation NSTEMI 48.60% 59.60% 54.90% 29.40% <0.001
– STEMI 51.40% 40.40% 45.10% 70.60% –
Drug-eluting Stent drug eluting stent 48.10% 67.90% 44.60% 38.10% <0.001
Access site Femoral 93.30% 90.90% 93.10% 95.50% 0.067
Age (years, median) 63 63 65 59 <0.001
BMI (median kg/m2) 27.17 27.34 27.02 27.34 0.119
eGFR (median ml/min) 88.68 91.61 82.73 96.52 <0.001
Baseline creatinine (median mg/dl) 0.9 0.9 0.97 0.9 0.053
SBP (median mm Hg) 140 140 135 140 0.758
CRP (median mg/l) 4 3.5 4.7 4 0.155
Baseline Hb (median g/dl) 14.15 14.1 13.8 14.5 <0.001
Baseline PLTs (median g/l) 232 230 233 231 0.603
Peak troponin (median ng/ml)b 13.97 9.55 9.53 26.62 <0.001
CK-MB (median U/l) 119 93 99.5 170 <0.001
Cardiovascular risk factors
Hypertension 77.50% 80.80% 78.00% 73.90% 0.105
Hyperlipidaemia 81.40% 81.20% 80.40% 83.20% 0.553
Smoking (current or prior) 50.80% 54.00% 44.30% 59.10% <0.001
Diabetes 26.00% 30.30% 27.30% 20.40% 0.011
Comorbidities
Previous MCI 15.00% 14.60% 16.80% 12.30% 0.173
Previous PCI 14.20% 16.40% 14.40% 12.00% 0.286
Previous CABG 2.90% 3.50% 3.20% 2.00% 0.440
Prior stroke or TIA 6.40% 7.00% 8.10% 3.10% 0.009
PAD 5.90% 5.90% 7.00% 3.90% 0.140
Atrial fibrillation 6.50% 5.60% 8.70% 3.40% 0.004
History for malignancies 5.30% 5.60% 6.70% 2.80% 0.033
Heart failure 11.60% 11.10% 11.20% 12.60% 0.786
Diseased vessels
1-VD (one vessel disease) 52.00% 50.20% 52.00% 53.50% 0.286
2-VD (two vessel disease) 30.60% 33.10% 31.90% 26.60% –
3-VD (three vessel disease) 17.30% 16.70% 16.10% 19.90% –
Medication therapy
ARB 13.10% 15.60% 11.40% 13.80% 0.217
Beta blocker 85.30% 86.10% 84.30% 86.40% 0.639
Statins 92.40% 96.50% 88.40% 95.80% <0.001
Acetylsalicylic acid 99.20% 99.10% 98.80% 100% 0.191
Antiplatelet substance
Clopidogrel 76.10% 68.30% 80.00% 75.90% <0.001
Prasugrel 13.90% 24.00% 9.40% 13.20% –
Ticagrelor 2.00 % 4.20% 1.80% 0.60% –
Othera 8.00% 3.50% 8.70% 10.40% –
UFH unfractionated heparin, GPI glycoprotein IIb/IIIa inhibitor, STEMI ST elevationmyocardial infarction, NSTEMI Non-ST elevationmyocardial infarction, BMI body
mass index, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, CRP baseline c-reactive protein levels, Hb haemoglobin, HCT baseline
haematocrit, PLT baseline platelet count, CK-MB creatine kinase myocardial band, MCI myocardial infarction, PCI percutaneous coronary intervention,
CABG coronary artery bypass graft, TIA transient ischemic attack, PAD peripheral artery disease, ARB angiotensin receptor blocker, VD vessel disease
*χ2-test/Kruska-Wallis test throughout three groups (pooled bivalirudin, UFH, UFH +GPI)
aOther refers to ticlopidin or inclusion in randomized trials with blinded treatment assignment
bUpper limit of normal for troponin I was 0.045 ng/ml
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Table 2 Unadjustedandadjusted3-year outcomesand ratesof stent thrombosis
Univariate outcomes
– All-cause death CV death
HR 95 % CI p-value HR 95% CI p-value
Pooled bivalirudin vs. UFH monotherapy 0.84 0.53; 1.34 0.47 0.76 0.41; 1.40 0.38
Pooled bivalirudin vs. UFH +GPI 1.16 0.67; 2.00 0.59 1.04 0.51; 2.10 0.92
Pooled bivalirudin vs. pooled UFH 0.94 0.60; 1.47 0.79 0.85 0.47; 1.52 0.57
UFH vs. UFH +GPI 1.34 0.88; 2.20 0.17 1.36 0.77; 2.41 0.29
Adjusted outcomes
– All-cause death CV death
HR 95 % CI p-value HR 95% CI p-value
Pooled bivalirudin vs. UFH monotherapy 1.12 0.68; 1.84 0.66 1.12 0.58; 2.16 0.73
Pooled bivalirudin vs. UFH +GPI 0.9 0.48; 1.71 0.75 0.91 0.40; 2.10 0.83
Pooled bivalirudin vs. pooled UFH 1.09 0.68; 1.76 0.71 1.08 0.58; 2.01 0.81
UFH monotherapy vs. UFH +GPI 0.76 0.46; 1.25 0.29 0.75 0.40; 1.41 0.37
Stent thrombosis
– All Definite Probable Acute Subacute p = 0.748*
Pooled bivalirudin 0.4 % 0.4 % 0% 0% 0.4% –
UFH monotherapy 0.8 % 0.5 % 0.3 % 0.3% 0.5% –
UFH +GPI 1.1 % 0.6 % 0.6 % 0.3% 0.8% –
UFH unfractionated heparin, GPI glycoprotein IIb/IIIa inhibitor, HR hazard ratio, CI confidence interval, CV cardiovascular
*χ2-test, multivariate adjustment not performed
abciximab (Table 1, p < 0.001). Moreover, bivalirudin
treated patients received one of the novel P2Y12-re-
ceptor inhibitors twice as frequently compared to
UFH-treated patients. In total, 88.9% of patients with
drug-eluting stent (DES) implantation received dual
antiplatelet therapy for 12 months, while 8.7% were
treated for 6–9 months only. Therapy durations that
were either shorter or longer were observed in 2.4%
of patients.
Mortality outcome
Patients were followed for up to 3 years after the index
hospitalization. In total, 113 (9.1%) events occurred.
Rates of all-cause death were 8.7%, 10.2% and 7.6% in
the pooled bivalirudin, UFH monotherapy and UFH +
abciximab groups, respectively. Corresponding rates
of cardiovascular death were 4.9%, 6.4% and 4.8%
after 3 years of follow-up, respectively. Univariate
analysis revealed non-significant different rates of all-
cause or cardiovascular death for bivalirudin vs. UFH
monotherapy, vs. UFH + abciximab and the pooled
UFH group as well as for UFH monotherapy vs. UFH +
abciximab (Table 2).
After adjustment for confounders, similar mortality
rates were observed for all comparisons. Univariate
and multivariate analyses are presented in Table 2.
Kaplan-Meier survival curves are shown in Fig. 1.
Stent thrombosis
Acute or subacute stent thrombosis occurred in 10
(0.8%) patients. In the pooled bivalirudin group 1
(0.4%) definite, subacute event occurred. In the UFH
monotherapy group, three definite and two probable
events occurred (0.8%) of which two were acute and
three subacute. In the UFH + abciximab group, we
observed two definite and two probable stent throm-
boses (1.1%) of which one event was acute. The differ-
ences between groups were not statistically significant
(p = 0.748) (Table 2).
Bleeding outcome
As shown in Fig. 2 composite rates of in-hospital TIMI
minor or major bleeding were 5.9% for the pooled
bivalirudin group, whereas these bleeding rates were
9.4% for the UFH monotherapy, 16% for the UFH +
abciximab group and 11.9% for the pooled UFH
group.
Univariate and multivariate analyses in the logistic
regression model are presented in Table 3.
After adjustment for confounding baseline vari-
ables bivalirudin use was associated with significantly
lower rates in the composite endpoint of TIMI minor
or major bleeding as compared to UFH + abciximab
(5.9% vs. 16%, OR 0.41, 95% CI 0.22–0.78, p = 0.01).
Adjusted rates of bleeding were non-significantly
lower for pooled bivalirudin vs. UFH monotherapy
(5.9% vs. 9.4%, OR 0.82, 95% CI 0.45–1.51, p = 0.53),
and were reduced by 35% comparing UFH alone
to UFH + abciximab (9.4% vs. 16%, OR 0.65, 95%
CI 0.43–0.99, p = 0.047). Comparing the pooled bi-
valirudin vs. the pooled UFH group, there was a
non-significant trend towards reduced bleeding rates
(5.9% vs. 11.9%, OR 0.62, 95% 0.36–1.08, p = 0.09).
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Fig. 1 Kaplan-Meier plots for all-causedeath (a) andcardiovascular death (b) after 3 years, stratified for antithrombotic treatment
strategy. OnpropensityscoreadjustedCoxregressionmodelling, therewerenosignificantdifferencesbetweengroupsforbothend-
points (Table2)













The year of treatment was accounted for in all ad-
justed analyses and the utilization of anticoagulants
over time is presented in Fig. 3.
Duration of hospitalization
Median days from PCI to hospital discharge are pre-
sented in Fig. 4. After adjustment for confounding
baseline variables major and minor bleeding pro-
longed post-PCI hospital stay by 6.5 (95%CI 4.5–8.5,
p < 0.01) and 3.2 (95% CI 2.0–4.3, p < 0.01) days,
respectively, as compared to patients without an in-
hospital bleeding episode.
Median days from PCI to hospital discharge were
5 (Interquartile range [IQR] 2;7), 5 (IQR 2; 7) and 7
(IQR 5; 8) in the pooled bivalirudin, UFH monother-
apy and UFH + abciximab groups, respectively. Af-
ter adjustment for confounders days from PCI to dis-
charge were similar between the pooled bivalirudin
and UFH monotherapy groups (–0.8, 95% CI –1.7 to
–0.06, p = 0.07) but reduced by 1.5 (95% CI –2.2 to
–0.7, p < 0.01) days compared to UFH + abciximab.
Discussion
In this retrospective analysis of a prospective registry,
reflecting a real world situation, we were able to con-
firm the results of most randomized controlled trials
in ACS patients undergoing invasive revascularization.
Bivalirudin use was associated with a 59% relative risk
reduction in periprocedural combined TIMI minor or
major bleeding rates compared to UFH +GPI, along
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Table 3 Unadjustedandadjusted in-hospitalminor ormajor bleeding rates
Univariate outcomes
OR 95 % CI p-value
Pooled bivalirudin vs. UFH monotherapy 0.61 0.35; 1.06 0.08
Pooled bivalirudin vs. UFH +GPI 0.33 0.19; 0.58 <0.01
Pooled bivalirudin vs. pooled UFH 0.47 0.28; 0.79 <0.01
UFH monotherapy vs. UFH +GPI 0.55 0.37; 0.81 <0.01
Adjusted outcomes
OR 95 % CI p-value
Pooled bivalirudin vs. UFH monotherapy 0.82 0.45; 1.51 0.53
Pooled bivalirudin vs. UFH +GPI 0.41 0.22; 0.78 0.01
Pooled bivalirudin vs. pooled UFH 0.62 0.36; 1.08 0.09
UFH monotherapy vs. UFH +GPI 0.65 0.43; 0.99 0.047
UFH unfractionated heparin, GPI glycoprotein IIb/IIIa inhibitor, OR odds ratio, CI confidence interval
Fig. 3 Utilizationof thedifferentantithromboticstrategiesover
time. Timely linked to thepublicationof theHORIZONS-AMI
trial, therewasasignificant increase inbivalirudinutilization,
whereasstrategies including abciximabwere less frequently
used thereafter
with a reduced hospital stay after PCI. Bleeding rates
were numerically but not statistically significantly
lower comparing pooled bivalirudin vs. UFH alone
or the pooled UFH group, whereas the rates of stent
thrombosis, all-cause death and cardiovascular death
were not statistically different between groups. Ab-
ciximab use increased significantly between 2006 and
2009 probably because of the recommendations is-
sued by the American College of Cardiology/American
Heart Association (ACC/AHA) guidelines on STEMI
(2004) and NSTEMI (2007) as well as by the European
Society of Cardiology (ESC) guidelines on the use of
antiplatelet agents (2004) [14–16]. Moreover, timely
linked to the publication of the HORIZONS-AMI trial
in 2008, there was a significant increase in bivalirudin
utilization, whereas strategies including abciximab
were less recommended and also used thereafter
[3]. This underlines the adherence to international
guidelines at our center.
Mortality outcome
Several earlier randomized trials conducted in the
setting of moderate to high-risk NSTEMI (ACUITY
and ISAR REACT 4) and STEMI (HORIZONS-AMI)
revealed a positive net clinical benefit in favor of
bivalirudin vs. UFH + GPI, primarily through the re-
duction of major bleeding events [3, 10, 11, 17]. The
more recent EUROMAX trial investigated bivalirudin
(with 12% GPI use) vs. UFH (with 69% GPI use) in
a modern treatment setting for STEMI (50% novel
P2Y12 inhibitors) and also demonstrated a positive
net clinical benefit in favor of bivalirudin. This benefit
was mainly achieved through the reduction of major
bleeding events, whereas cardiac death was not af-
fected by the choice of the anticoagulant [7]. As the
use of GPIs is usually low in a contemporary clinical
setting, while radial access and novel P2Y12 receptor
inhibitors are increasingly being used, the compar-
ison vs. UFH monotherapy is particularly desirable
[18]. The BRIGHT trial randomly assigned 2194 STEMI
patients to bivalirudin with a 3-h postprocedural in-
fusion, UFH alone or UFH + tirofiban and reported
no significant differences regarding major adverse
cardiac or cerebral events at 30 days [8]. The recent
MATRIX trial randomized 7213 ACS patients to either
bivalirudin or UFH alone (only 0.2% GPI use) and
did not show a net improvement in adverse clinical
events. Although cardiac death was reduced by 32%
(likely through reduction of major bleeding), this was
counterbalanced by an excess in definite stent throm-
bosis [4]. In the single center HEAT-PPCI trial, also
conducted in a modern setting (15% GPI bail-out use,
90% novel P2Y12 receptor inhibitors and over 80% ra-
dial access) major adverse cardiovascular events were
significantly increased by 52% in the bivalirudin arm,
with a fourfold risk of stent thrombosis and also an
increase in bleeding hazards [9]. Meta-analyses pro-
vided conflicting results depending on the selection
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Fig. 4 Mediandays fromPCI tohospital discharge for theoverall cohortandstratifiedbyclinical presentationandbleedingseverity.
Onadjustment for confounders,major andminorbleedingprolongedpost-PCIhospital stayby6.5 (95%CI4.5–8.5,p<0.01)and3.2
(95%CI2.0–4.3,p<0.01) days, respectively, compared topatientsnot experiencing ableeding episode
of these trials regarding reinfarction but showed no
differences in mortality despite an increase in acute
stent thrombosis in bivalirudin treated patients [19,
20]. In line with these findings we did not observe a
mortality difference between groups, keeping in mind
that statistical power was limited due to low sample
size.
Stent thrombosis
The rate of stent thrombosis was in the range of pre-
viously published data, also considering that 51% of
patients received bare metal stents [21]. We did not
observe significant differences between groups; how-
ever, event rates were too low for statistical adjust-
ment for confounders. In this setting there was no ex-
cess in acute stent thrombosis in patients treated with
bivalirudin, opposed to data from previous large-scale
trials [4, 7, 9].
Bleeding outcomes
Our data are similar to the findings from the HORI-
ZONS-AMI, EUROMAX, ACUITY, ISAR-REACT 4, and
REPLACE-2 trials regarding significantly reduced
bleeding hazards for bivalirudin vs. UFH + GPI [3,
7, 10, 11, 22]. As expected, we also observed lower
bleeding rates when UFH monotherapy was com-
pared to UFH + abciximab. It has to be noted that
from a clinical point of view, comparisons against
UFH + GPI are less relevant as recent guidelines rec-
ommend to restrict GPI use to bail-out situations [18,
23].
Data from prospective, randomized trials compar-
ing bivalirudin and UFH monotherapies with respect
to bleeding rates pointed in the same direction in
both stable and ACS patients: [4, 8, 24]. In the recent
BRIGHT and MATRIX trials, bleeding rates were sig-
nificantly lower in favor of bivalirudin vs. UFH alone
even when bivalirudin was continued following the
procedure [4, 8]. Interestingly, no differences in ma-
jor bleeding could be observed in the HEAT-PPCI trial
[9] conducted in a modern setting with respect to an-
tiplatelet agents, access site and GPI use. A poten-
tial explanation could be the prominent use of new
P2Y12 receptor inhibitors that are known to be asso-
ciated with significantly higher spontaneous bleeding
rates [5, 25]. This was further confirmed by a post
hoc analysis of EUROMAX demonstrating similar clin-
ical outcome but higher per protocol major bleeding
rates in patients treated with prasugrel or ticagrelor
as compared to clopidogrel [26]. Although in-hospital
bleeding rates in ACS patients undergoing PCI might
also depend on the vascular access site and the ma-
jority of femoral access in our study might have in-
fluenced bleeding rates, a recent analysis has shown
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benefits for bivalirudin over UFH monotherapy and
over UFH +GPI for both access sites [7].
Hospital stay
The occurrence of TIMI minor and major bleeding
had a substantial impact on post-PCI hospital stay in
our analysis. As also described by others, major bleed-
ing hazards accounted for an almost twofold prolon-
gation of hospitalization in ACS patients [27]. Thus,
preventing bleeding is important to preserve health-
care resource consumption, in addition to optimizing
clinical outcomes.
Limitations
The data from the present study were collected from a
single center and in a non-randomized fashion as the
treatment strategy was at the discretion of the treating
interventional cardiologist; however, the 100% follow-
up rate strengthens the quality of data collection in
this registry. Moreover, the number of patients in the
bivalirudin arm was relatively low. This is mainly due
to the fact that the majority of patients were included
before publication of the recent NSTEMI and STEMI
guidelines recommending bivalirudin monotherapy
over UFH and UFH + GPI [28, 29]. Potential dif-
ferences between treatment groups were existent but
were accounted for in propensity score-adjustedmod-
els. Finally, additional safety and efficacy endpoints
such as stroke, reinfarction, stent thrombosis, repeat
revascularization, transfusion and thrombocytopenia,
which may vary between the study regimens, are not
available. Our findings might not apply to patients
treated via a radial approach.
Conclusion
This real world experience in patients presenting with
ACS and undergoing PCI and stent implantation in-
dicates that bivalirudin is clinically similar to UFH
monotherapy but superior to UFH + abciximab with
respect to the reduction of bleeding events, which in
turn was associated with a shorter hospital stay. The
rate of stent thrombosis as well as long-term clini-
cal outcomes in terms of all-cause and cardiovascular
mortality were statistically similar between groups.
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